Smoking Cessation Labels Cleared Without Duration-Of-Use Limit
This article was originally published in The Tan Sheet
Executive Summary
FDA approved labeling for Nicorette and NicoDerm CQ nicotine replacement therapies, removing some risk information that industry and the agency agree is outdated and unnecessarily restrictive.
You may also be interested in...
FDA's Nicotine Replacement Standards Review Could Open Door For E-Cigarettes
Latest steps by US FDA targeting tobacco-related health problems are a Nicotine Steering Committee, headed by Commissioner Gottlieb, and a public docket, including a meeting in January, for suggestions on how novel products could be evaluated as safe and effective NRTs.
FDA's Nicotine Replacement Standards Review Could Open Door For E-Cigarettes
Latest steps by US FDA targeting tobacco-related health problems are a Nicotine Steering Committee, headed by Commissioner Gottlieb, and a public docket, including a meeting in January, for suggestions on how novel products could be evaluated as safe and effective NRTs.
Smoking Cessation Label Changes Could Lay Groundwork For Indications
FDA drops its requirement for labeling provisions for NRTs on duration of use and concomitant use of tobacco or other NRTs. Meanwhile, the agency rejects citizen petition requests for additional NRT indications, but says it is open to working with sponsors on developing those indications.